Brand Case Study: Zydus Lipaglyn™

Brand Name: Lipaglyn 

Molecule: saroglitazar

Launched date: Launched in September 2013 in India

Indications positioned for:  for treating hypertriglyceridemia and diabetic dyslipidemia in patients with type 2 diabetes not controlled by statins.

Since then, more than 80,000 patients are availing this drug with a prescriber base over 3500 diabetologists, cardiologists and physicians. Lipaglyn helps in a reduction of triglycerides and LDL (bad) cholesterol, and an increase in HDL (good) cholesterol and has also shown a reduction in Fasting Plasma Glucose and glycosylated haemoglobin (HbA1c), thereby confirming its beneficial effects on both lipid and glycemic control in diabetic patients. Lipaglyn is a prescription medicine, and can be taken only under the advice and guidance of a registered medical practitioner.

Zydus Cadila, an Ahmedabad-based innovative, global pharmaceutical company, announced that the company has presented new scientific and clinical data on saroglitazar at the 75th Annual Scientific Sessions of the American Diabetes Association (ADA) in Boston, Massachusetts, USA.

About Lipaglyn:

Lipaglyn™ is the first Glitazar to be approved in the world and is the first New Chemical Entity (NCE) discovered and developed indigenously by an Indian Pharma Company.

Lipaglyn™, is a novel drug targeted at bridging an unmet healthcare need for treating Diabetic Dyslipidemia or Hypertriglyceridemia in type 2 diabetes, not controlled by statins alone. The drug has been approved for launch in India by the Drug Controller General of India (DCGI). With a novel action that offers lipid and glucose lowering effects in one molecule, Lipaglyn™ is the first Glitazar to be approved anywhere in the world.

Lipaglyn™ is a prescription drug, currently available for sale in India only.

Discovered by the Zydus Research Centre, the dedicated NCE research arm of the Zydus group, Lipaglyn™ is a best-in-class innovation, designed to have a unique cellular mechanism of action following an extensive structure-activity relationship study initiated in the year 2000. Lipaglyn™ has a predominant affinity to PPAR alpha isoform and moderate affinity to PPAR gamma isoform of PPAR nuclear receptor sub-family. The molecule has shown beneficial effects on lipids and glycemic control without side effects. This molecule underwent extensive pre-clinical characterisation and the Investigational New Drug (IND) was submitted in the year 2004.